ArticlePloS one2013
Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 50 citations in OpenAlex.
- Expression of bluetongue virus core proteins VP2 and VP7 by bovine herpesvirus-4 confers protection against virulent challenge in a mouse model.Veterinary research · 2026Article
- Unleashing the immune arsenal: development of broad spectrum multiepitope bluetongue vaccine targeting conserved T cell epitopes of structural proteins.BMC genomics · 2026Article
- Safety and Efficacy of Plant-Produced Trivalent Virus-Like Particle Vaccine Candidate Against Bluetongue Disease.Plant biotechnology journal · 2026Article
- Age- and Sex-Associated Pathogenesis of Cell Culture-Passaged Kemerovo Virus in IFNARInternational journal of molecular sciences · 2024Article
- Co-expression of VP2, NS1 and NS2-Nt proteins by an MVA viral vector induces complete protection against bluetongue virus.Frontiers in immunology · 2024Article
- Immuno-informatics study identifies conserved T cell epitopes in non-structural proteins of Bluetongue virus serotypes: formulation of a computationally optimized next-generation broad-spectrum multi-epitope vaccine.Frontiers in immunology · 2024Article
- Article
- Increased Clinical Signs and Mortality in IFNARPathogens (Basel, Switzerland) · 2023Article
- Pathological features of African horse sickness virus infection in IFNARFrontiers in veterinary science · 2023Article
- Recombinant Modified Vaccinia Virus Ankara Development to Express VP2, NS1, and VP7 Proteins of Bluetongue Virus.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Article
- Inhibition of Orbivirus Replication by Fluvastatin and Identification of the Key Elements of the Mevalonate Pathway Involved.Viruses · 2021Article
- Pathological and immunological characterization of bluetongue virus serotype 1 infection in type I interferons blocked immunocompetent adult mice.Journal of advanced research · 2021Article
- Viral Vector Vaccines against Bluetongue Virus.Microorganisms · 2020Review
- An updated review on bluetongue virus: epidemiology, pathobiology, and advances in diagnosis and control with special reference to India.The veterinary quarterly · 2020Review
- A protective bivalent vaccine against Rift Valley fever and bluetongue.NPJ vaccines · 2020Article
- Bluetongue virus outer-capsid protein VP2 expressed inVaccine: X · 2019Article
- Constructing a High-Density Genetic Linkage Map for Large Yellow Croaker (Larimichthys crocea) and Mapping Resistance Trait Against Ciliate Parasite Cryptocaryon irritans.Marine biotechnology (New York, N.Y.) · 2019Article
- Review
- Prospects of Next-Generation Vaccines for Bluetongue.Frontiers in veterinary science · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
Abstract
The protective efficacy of recombinant vaccines expressing serotype 8 bluetongue virus (BTV-8) capsid proteins was tested in a mouse model. The recombinant vaccines comprised plasmid DNA or Modified Vaccinia Ankara viruses encoding BTV VP2, VP5 or VP7 proteins. These constructs were administered alone or in combination using either a homologous prime boost vaccination regime (rMVA/rMVA) or a heterologous vaccination regime (DNA/rMVA). The DNA/rMVA or rMVA/rMVA prime-boost were administered at a three week interval and all of the animals that received VP2 generated neutralising antibodies. The vaccinated and non-vaccinated-control mice were subsequently challenged with a lethal dose of BTV-8. Mice vaccinated with VP7 alone were not protected. However, mice vaccinated with DNA/rMVA or rMVA/rMVA expressing VP2, VP5 and VP7 or VP2 alone were all protected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.